Navigation Links
Results of the DEB-AMI Trial reported at TCT 2011
Date:11/10/2011

SAN FRANCISCO, CA NOVEMBER 10, 2011 A clinical trial that compared the use of drug-eluting balloons (DEB) and bare metal stents (BMS) to both bare metal stents alone and drug-eluting stents (DES) found that the drug-eluting balloon group did not meet the primary endpoint of reduced late lumen loss. Results of the DEB-AMI (Drug Eluting Balloon in Acute Myocardial Infarction) trial were presented today at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

Concerns regarding the safety of DES in ST-segment elevated acute myocardial infarctions (STEMI) continue to exist, including the risk of stent thrombosis. The use of drug-eluting balloons in angioplasty show potential as an alternative to treat STEMI.

In this randomized, international two-center, single-blinded three-arm study, patients were randomly assigned (ratio 1:1:1) to one of the following treatment groups: DEB plus BMS (n=50); BMS (n=50); or DES (n=49) after successful thrombus aspiration.

All patients underwent stenting with an identical stent platform. The primary endpoint was six- month angiographic late lumen loss. Secondary end points were six-month binary restenosis, stent malapposition and re-endothelialization assessed by OCT, endothelial function assessed through acetylcholine testing, and major adverse cardiac events (MACE: death, myocardial infarction, target vessel revascularization).

Late lumen loss at six months was as follows:

  • DEB+BMS: 0.640.56
  • BMS: 0.780.59
  • DES: 0.210.32

The rates of major adverse cardiac events were as follows:

  • DEB+BMS: 10 (20.0%)
  • BMS: 12 (23.5%)
  • DES: 2 (4.1%)

"Results of the DEB-AMI trial indicate that drug-eluting stents induce more pronounced morphological changes (compared to drug-eluting balloons), resulting in superior angiographical and clinical outcomes with respect to bare metal stents and drug-eluting stents," said Pieter R. Stella, MD, PhD, the lead investigator of the trial. Dr. Stella is Director of the Heart Catheterization Laboratories and Director of Clinical Cardiovascular Research at the University Medical Centre Utrecht in The Netherlands.

Researchers noted however, that experience of the operators and discrepancies between the two trial sites may have impacted the findings.


'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Results of the RIFLE STEACS clinical trial reported at TCT 2011
2. Results of the PARTNER Trial Cohort B 2-year follow up presented at TCT 2011
3. Results of the PARTNER Trial Cohort A cost effectiveness analysis reported
4. Combination epigenetic therapy clinical trial results
5. Results of the PARIS registry Reported at TCT 2011
6. Results of the TRIGGER-PCI trial reported at TCT 2011
7. Results of rapid gene trial reported at TCT 2011
8. Results of the BRIDGE trial reported at TCT 2011
9. First results of Angiomax (bivalirudin) vs. heparin in transcatheter aortic valve interventions
10. Osteoarthritis results from inflammatory processes, not just wear and tear, Stanford study suggests
11. E-counselling shows dramatic results in lowering blood pressure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... financial planning, and related services to families and business owners across eastern Michigan, ... at feeding regional families struggling with financial difficulties. , The Oxford/Orion FISH Food ...
(Date:3/24/2017)... PA (PRWEB) , ... March 24, 2017 , ... ... Oncology Nursing Society (ONS) wanted to create a communications platform that positions them ... this goal, Elliance and ONS reinvented their online publication as an always-on, always-fresh ...
(Date:3/24/2017)... ... March 24, 2017 , ... The law firm of Enea, ... pleased to announce Westchester resident Lauren C. Enea has joined the firm as an ... will concentrate her practice in elder law, Medicaid planning and applications, and Wills, Trusts ...
(Date:3/24/2017)... ... 2017 , ... Empower Brokerage, located in Southlake, Texas, intends ... , In February, 2017, Empower Brokerage introduced their new “Performance Partners” program to ... teach how to maximize their sales efforts, as well as how to best ...
(Date:3/24/2017)... ... 24, 2017 , ... “End Time GPS”: a dauntless and enlightened study ... Time GPS” is the creation of published author, Wesley Gerboth, a World War II ... and space-vehicle projects. Now, at age ninety-one, he shares the Wisdom God bestowed upon ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... report to their offering. ... The report provides separate comprehensive analytics for the US, Canada ... Asia-Pacific , Latin America , and ... 2015 through 2022. Also, a six-year historic analysis is provided for these ...
(Date:3/24/2017)... surveys with 9,250 insured consumers fielded from February 2015 ... help from their plans in five key areas: 1) ... help closing gaps in care, 3) better digital connections, ... real-time guidance. Meeting these needs is essential to promoting ... A Reason to Stay Engaged in Health ...
(Date:3/24/2017)... GENEVA , March 24, 2017 ... revitalizes efforts to develop sutezolid as effective response to ... Day, TB Alliance and the Medicines Patent Pool (MPP) ... sutezolid, an antibiotic drug candidate which demonstrated encouraging results ... of sutezolid in combination with other TB drugs and ...
Breaking Medicine Technology: